Reproducibility of (18)F-FDG PET uptake measurements in head and neck squamous cell carcinoma on both PET/CT and PET/MR

TY - JOUR

T1 - Reproducibility of (18)F-FDG PET uptake measurements in head and neck squamous cell carcinoma on both PET/CT and PET/MR

AU - Rasmussen, J H

AU - Fischer, B M

AU - Aznar, M C

AU - Hansen, A E

AU - Vogelius, I R

AU - Löfgren, J

AU - Andersen, F L

AU - Loft, A

AU - Kjaer, A

AU - Højgaard, L

AU - Specht, L

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Objective: To investigate reproducibility of fluorine-18 fludeoxyglucose (18F-FDG) uptake on 18F-FDG positron emission tomography (PET)/CT and 18F-FDG PET/MR scans in patients with head and neck squamous cell carcinoma (HNSCC). Methods: 30 patients with HNSCC were included in this prospective study. The patients were scanned twice before radiotherapy treatment with both PET/CT and PET/MR. Patients were scanned on the same scanners, 3 days apart and according to the same protocol. Metabolic tumour activity was measured by the maximum and peak standardized uptake value (SUVmax and SUVpeak, respectively), and total lesion glycolysis from the metabolic tumour volume defined from $50% SUVmax. Bland-Altman analysis with limits of agreement, coefficient of variation (CV) from the two modalities were performed in order to test the reproducibility. Furthermore, CVs from SUVmax and SUVpeak were compared. The area under the curve from cumulative SUV-volume histograms were measured and tested for reproducibility of the distribution of 18F-FDG uptake. Results: 24 patients had two pre-treatment PET/CT scans and 21 patients had two pre-treatment PET/MR scans available for further analyses. Mean difference for SUVmax, peak and mean was approximately 4% for PET/CT and 3% for PET/MR, with 95% limits of agreement less than 620%. CV was small (5-7%) for both modalities. There was no significant difference in CVs between PET/CT and PET/MR (p50.31). SUVmax was not more reproducible than SUVpeak (p50.09). Conclusion: 18F-FDG uptake in PET/CT and PET/MR is highly reproducible and we found no difference in reproducibility between PET/CT and PET/MR. Advances in knowledge: This is the first report to test reproducibility of PET/CT and PET/MR.

AB - Objective: To investigate reproducibility of fluorine-18 fludeoxyglucose (18F-FDG) uptake on 18F-FDG positron emission tomography (PET)/CT and 18F-FDG PET/MR scans in patients with head and neck squamous cell carcinoma (HNSCC). Methods: 30 patients with HNSCC were included in this prospective study. The patients were scanned twice before radiotherapy treatment with both PET/CT and PET/MR. Patients were scanned on the same scanners, 3 days apart and according to the same protocol. Metabolic tumour activity was measured by the maximum and peak standardized uptake value (SUVmax and SUVpeak, respectively), and total lesion glycolysis from the metabolic tumour volume defined from $50% SUVmax. Bland-Altman analysis with limits of agreement, coefficient of variation (CV) from the two modalities were performed in order to test the reproducibility. Furthermore, CVs from SUVmax and SUVpeak were compared. The area under the curve from cumulative SUV-volume histograms were measured and tested for reproducibility of the distribution of 18F-FDG uptake. Results: 24 patients had two pre-treatment PET/CT scans and 21 patients had two pre-treatment PET/MR scans available for further analyses. Mean difference for SUVmax, peak and mean was approximately 4% for PET/CT and 3% for PET/MR, with 95% limits of agreement less than 620%. CV was small (5-7%) for both modalities. There was no significant difference in CVs between PET/CT and PET/MR (p50.31). SUVmax was not more reproducible than SUVpeak (p50.09). Conclusion: 18F-FDG uptake in PET/CT and PET/MR is highly reproducible and we found no difference in reproducibility between PET/CT and PET/MR. Advances in knowledge: This is the first report to test reproducibility of PET/CT and PET/MR.

KW - Adult

KW - Aged

KW - Algorithms

KW - Carcinoma, Squamous Cell

KW - Female

KW - Fluorodeoxyglucose F18

KW - Head and Neck Neoplasms

KW - Humans

KW - Image Interpretation, Computer-Assisted

KW - Magnetic Resonance Imaging

KW - Male

KW - Middle Aged

KW - Multimodal Imaging

KW - Neoplasm Staging

KW - Positron-Emission Tomography

KW - Prospective Studies

KW - Radiopharmaceuticals

KW - Reproducibility of Results

KW - Tomography, X-Ray Computed

U2 - 10.1259/bjr.20140655

DO - 10.1259/bjr.20140655

M3 - Journal article

C2 - 25634069

SN - 0007-1285

VL - 88

SP - 20140655

JO - British Journal of Radiology

JF - British Journal of Radiology

IS - 1048

ER -